To hear about similar clinical trials, please enter your email below
Trial Title:
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
NCT ID:
NCT06557304
Condition:
CLL
Conditions: Official terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Drug
Intervention name:
BTK inhibitor
Description:
patients with treatment naive or R/R CLL who treatment with BTK inhibitor
Summary:
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of
Chronic Lymphocytic Leukemia in China
Criteria for eligibility:
Study pop:
Investigators participating in this observational study should include all patients with
CLL who initiated treatment with BTK inhibitor over the period from Dec. 1st, 2017 to the
present, regardless of the treatment status at the time of inclusion. Thus, at the time
of enrolment and retrospective data collection, patients may still be on treatment or
have stopped treatment for any reason.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Patients aged ≥18 years old
2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring
treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK
inhibitor;
4. Prior or current use of BTK inhibitor for ≥3 months
5. At least one follow-up was recorded during BTK inhibitor treatment
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
September 1, 2024
Completion date:
December 30, 2027
Lead sponsor:
Agency:
Peking University People's Hospital
Agency class:
Other
Source:
Peking University People's Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06557304
